Hormone deprivation cannot cure prostate cancerJanuary 1st, 2009 - 11:25 am ICT by IANS
Washington, Jan 1 (IANS) Hormone deprivation therapy in prostate cancer only provides temporary relief, with tumours usually regaining their hold within a couple of years. Now, researchers have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings could open a way to track disease progression.Prostate cancer cells rely on androgens, male hormones that include testosterone, to survive and grow, explained Jun Luo, assistant professor at Johns Hopkins’ James Buchanan Brady Urological Institute.
Since 1941, doctors have taken advantage of this dependency to battle prostate cancer by depriving patients of androgens, either by castration or chemical methods.
For most patients, this hormone deprivation therapy causes tumours to shrink, sometimes dramatically. However, it’s never a cure. Tumours eventually regrow into a stronger form, becoming resistant to this and other forms of treatment.
Seeking the reason why this therapy eventually fails, Luo and his colleagues at the Johns Hopkins University School of Medicine, University of Washington and Puget Sound VA Medical Centre looked to a key player: the androgen receptors on prostate cancer cells.
Using a large database, researchers searched for variations of the nucleic acid RNA that prostate cells use to create androgen receptors, eventually identifying seven RNA sequences different from the “normal” androgen receptor already known to scientists.
When they looked for these sequences in cells isolated from 124 prostate cancer patients, they found over-production of these outlaw variants in prostate cancer cells taken from patients whose disease had become resistant to hormone deprivation therapy.
One variation, known as AR-V7, was also prevalent in a select group of patients who had never taken hormone therapy, but whose cancer aggressively regrew after surgery to remove their tumours, said a Johns Hopkins release.
The results suggest that hormone therapy might encourage prostate cancer cells to overproduce the AR-V7 receptors over time, leading them to survive and grow aggressively even without androgens, explained Luo.
These findings appeared in Thursday’s issue of Cancer Research.
- Why prostate cancer patients become resistant to hormone deprivation therapy - Jan 01, 2009
- Gene fusion is the 'smoking gun' in the development of prostate cancer: Study - May 19, 2010
- Australian scientists identify new way to treat prostate cancer - Feb 26, 2010
- Cancer 'wonder drug' launched in Britain - Sep 21, 2011
- Protein that protects against prostate cancer discovered - Feb 01, 2011
- Molecule discovery good news for prostate cancer sufferers - Dec 29, 2009
- Surgery effective for aggressive prostate cancer patients - Sep 28, 2010
- Hormone therapy 'doubles survival chances in men with prostate cancer' - Mar 25, 2011
- Prostate cancer treatment 'ups risk of colorectal cancer' - Nov 16, 2010
- Potent anticancer drug isolated from weed - Jul 10, 2012
- Experimental drug for advanced prostate cancer shows promise - Apr 15, 2010
- New process to 'program' cancer cell death created - Sep 08, 2010
- Vitamin C hastens brain tumour's death - Feb 20, 2012
- Trio of drugs may help fight 'triple negative' breast cancer - Dec 11, 2010
- Why PSA levels reflect prostate cancer progression - Jan 14, 2011
Tags: androgen receptors, brady urological institute, hormone receptors, johns hopkins university, johns hopkins university school, johns hopkins university school of medicine, prostate cancer cells, prostate cancer patients, prostate cells, rna sequences